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Extended-Spectrum Beta-Lactamase-
Producing Salmonella Enteritidis in
Trinidad and Tobago
To the Editor: Salmonella Enteritidis, a
predominantly localized pathogen of the human
gastrointestinal tract, can become invasive in
very young, very old, malnourished, and
immunocompromised patients. In recent years,
S. Enteritidis has emerged as a major intestinal
pathogen in Trinidad and Tobago (population 1.2
million); in 1997, S. Enteritidis caused 79 (66%)
of 119 culture-confirmed salmonella infections,
in contrast to 18 (18%) of 99, 48 (47%) of 102, and
107 (61%) of 178 in 1994, 1995, and 1996,
respectively. Increased incidence of S. Enteriti-
dis infections has been reported worldwide (1,2).
Of 216 human S. Enteritidis isolates tested for
antimicrobial susceptibility between 1994 and
1996 in Trinidad, none were resistant to
cephalosporins, aminoglycosides, ampicillin,
trimethoprim-sulphamethoxazole, chlorampheni-
col, and norfloxacin/ciprofloxacin by the Kirby-
Bauer disk diffusion method, which uses the
National Committee for Clinical Laboratory
Standards (NCCLS) breakpoints (3).
Here we report an unusual isolate of
S.  Enteritidis resistant to all penicillins and
cephalosporinsincluding third-generation
cephalosporins, gentamicin, tobramicin, and
trimethoprim-sulphamethoxazoleby the Kirby-
Bauer disk diffusion method. Amoxicillin-
clavulanate and piperacillin-tazobactam disks
gave zone sizes of 15 mm and 19 mm,
respectively, which are classified as intermedi-
ate in the NCCLS guidelines. This isolate was
recovered from the blood culture of a febrile,
nonneutropenic patient with multiple myeloma
on two occasions 24 hours apart in March 1998.
The isolate was sensitive only to ofloxacin and
imipenem. Admitted to the hospital with
compressed fracture of the spine for physio-
therapy in December 1997, the patient had
several febrile episodes and received several
courses of multiple empirically prescribed
antibiotics (cefotaxime, gentamicin, and
piperacillin). The patient had not traveled
abroad during the previous 6 months.
Because cephalosporin resistance in salmo-
nellae has not been reported before in the
Caribbean, we investigated the mechanism
behind this third-generation cephalosporin
resistance further. Using amoxicillin-clavulanate
in combination with ceftazidime, ceftriaxone,
and aztreonam, we performed the double disk
synergy test to determine whether this strain
was an extended-spectrum beta-lactamase
producer as described elsewhere (3); augmenta-
tion of the zone at the junction of amoxicillin-
clavulanate and aztreonam/ceftriaxone/
ceftazidime zones confirmed that indeed it was.
In the past few years, third-generation
cephalosporin resistance in S. Enteritidis has
been described in Europe (4), the United States
(5), Turkey (6), India (7,8), and Argentina (9).
Few reports exist of extended-spectrum beta-
lactamasemediated third-generation cepha-
losporin resistance in Salmonella spp. To our
knowledge, this is the first report of this type of
resistance among S. Enteritidis in the Caribbean.
This patient was treated with ciprofloxacin for 1
week; subsequent blood cultures were negative.
This unusual isolate highlights the need to
establish an antimicrobial resistance surveil-
lance network for Salmonella isolates, including
S. Enteritidis, to monitor the trends and new
types of resistance mechanisms in the Carib-
bean. An epidemiologic study of S. Enteritidis
infections is being planned to describe the extent
of the problem and to define risk factors and
vehicles of human infections in three Caribbean
countries, including Trinidad and Tobago.
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New emm (M Protein Gene) Sequences of
Group A Streptococci Isolated from
Malaysian Patients
To the Editor: We analyzed the M-typespecific
emm gene sequences of 24 random Streptococcus
pyogenes isolates from sterile- and nonsterile-
site clinical specimens of Malaysian patients. In
contrast to isolates in the United States, which
rarely have new emm sequences, 6 of these 24
Malaysian isolates had new emm gene se-
quences, which suggests a large reservoir of
group A streptococci expressing new M-type
specificities in Malaysia.
The M protein is a surface-exposed principal
virulence factor of group A streptococci (GAS)
and a potential vaccine candidate. The
hypervariable M-typespecific N-terminal por-
tion of the M molecule extends from the cell wall
and evokes protective antibodies. Approximately
75 M antigenic types of GAS are recognized, and
several provisional types have been proposed (1).
Formulation of a universally effective vaccine is
complicated by the M-typespecific nature of
protective anti-GAS antibodies, temporal and
geographic variations in GAS M-type prevalence
(2), and lack of information on GAS M types from
areas where rheumatic fever and rheumatic
heart disease, sequelae of GAS pharyngitis, are
endemic (3). The lack of specific M-typing antisera
is also a limiting factor in determining type
distribution. Recently, Beall and colleagues (4,5)
demonstrated that sequence analysis of the
hypervariable portion of the emm gene encoding
M-type specificity (emm typing) was an alternative
when M-typing antisera were not available.
Attempts to type selected Malaysian strains
of GAS by M protein status have yielded poor
results. Fewer than 16% of strains were typable
with standard M-typing antisera (6). The
existence of new M types in Southeast Asia was
suggested as an explanation. To investigate this
possibility, we subjected 27 selected strains (6
from blood, 15 from pharyngitis, 3 from pus, and
3 pharyngeal carrier cultures) collected between
January 1994 and December 1996 to emm
typing. Initial isolation, serogrouping, T typing,
and determination of opacity factor production
were performed in Kuala Lumpur, by standard
techniques, commercial media, reagents, and
antisera (7). Strains were transported to the
Centers for Disease Control and Prevention in
Atlanta, Georgia, USA, for emm typing, where
serogrouping, T typing, and opacity factor
determinations were repeated, and emm typing
was performed (4,5). DNA sequences were
subjected to homology searches against all
known  emm sequences by Genetics Computer
Group Software, Version 9. (Most sequences in
this database were found in strains isolated from
patients living in Europe and North America.)
Of the 27 cultures analyzed, 24 were GAS, 2
were group G streptococci, and 1 was
nongroupable Streptococcus. Ten of the 24 GAS
strains were standard emm types emm3, emm12,
emm22,  emm60, and emm76 (encoding the
classic M types M3, M12, M22, M60, and M76,
respectively); 4 were the provisional emm types
pt180, pt2841, and pt5757; and 3 were previously
identified  emm  sequence types st64/14 and
st2034 (GenBank accession numbers X72932 and
U74320, respectively). The st2034 sequence,
originally identified in children from Papua New
Guinea, has also been found in Brazil, California,
and Hawaii (B. Beall, R. Facklam, unpub. data).
One GAS had a sequence previously found in
group G streptococci (emmLG6, accession
number U25741). Finally, 6 were of five new
emm sequence types discovered in this study